CA 125 AS A MARKER OF TUMOR ACTIVITY IN ADVANCED UROTHELIAL MALIGNANCY
- 1 June 2001
- journal article
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 165 (6 Part 1) , 1908-1913
- https://doi.org/10.1016/s0022-5347(05)66240-4
Abstract
No abstract availableThis publication has 25 references indexed in Scilit:
- Clinical evaluation of the BTA trak assay and comparison to voided urine cytology and the bard BTA test in patients with recurrent bladder tumorsUrology, 1997
- Genetic studies and molecular markers of bladder cancerSeminars in Surgical Oncology, 1997
- TPA, TATI, CEA, AFP, β-HCG, PSA, SCC, and CA 19-9 for Monitoring Transitional Cell Carcinoma of the BladderAmerican Journal of Clinical Oncology, 1996
- Cancer statistics, 1995CA: A Cancer Journal for Clinicians, 1995
- Serial CA 125 Levels During Chemotherapy for Metastatic or Recurrent Endometrial CancerObstetrics & Gynecology, 1991
- Blood group-related antigens as markers of malignant potential and heterogeneity in human carcinomasHuman Pathology, 1986
- Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive SystemThe Lancet Healthy Longevity, 1986
- A Radioimmunoassay Using a Monoclonal Antibody to Monitor the Course of Epithelial Ovarian CancerNew England Journal of Medicine, 1983
- Preoperative Carcinoembryonic Antigen Level as a Prognostic Indicator in Colorectal CancerNew England Journal of Medicine, 1978
- Demonstration of an Antigen Common to Several Varieties of NeoplasiaNew England Journal of Medicine, 1971